Protein kinase C (PKC) is a closely related family of Ca2+/ phospholipid-dependent kinases which have been identified in a wide range of tissues, including islets of Langerhans and insulin-secreting tumour cells (for review see, [ 11). PKC activity is thought to be regulated by the availability of diacylglycerols (DAG) which are generated by synthesis de novo, or by the phospholipase C-mediated hydrolysis of membrane phospholipids in response to glucose, cholinergic agonists or depolarization (reviewed in [2]). A role for PKC in insulin secretion is suggested by the fact that DAG analogues or phorbol esters, which substitute for DAG [3] , can stimulate insulin secretion (for references, see [ 21).
Protein kinase C (PKC) is a closely related family of Ca2+/ phospholipid-dependent kinases which have been identified in a wide range of tissues, including islets of Langerhans and insulin-secreting tumour cells (for review see, [ 11) . PKC activity is thought to be regulated by the availability of diacylglycerols (DAG) which are generated by synthesis de novo, or by the phospholipase C-mediated hydrolysis of membrane phospholipids in response to glucose, cholinergic agonists or depolarization (reviewed in [2] ). A role for PKC in insulin secretion is suggested by the fact that DAG analogues or phorbol esters, which substitute for DAG [3] , can stimulate insulin secretion (for references, see [ 21) .
Studies of the role of PKC in insulin secretion using inhibitors of PKC activity are often difficult to interpret because of the questionable specificity of many inhibitors [4-61. We have therefore investigated the functional role of PKC in the regulation of insulin secretion from isolated rat islets of Langerhans by measuring the secretory responses of normal and PKC-depleted islets to insulin secretagogues, and by correlating secretory responses to the activation and redistribution of PKC within islets. These studies used islets isolated from rat pancreas by collagenase digestion and maintained in tissue culture for 20-24 h [7, 81. Insulin secretion was measured by radioimmunoassay [ 91 and ion-exchange purified PKC activity was measured by phosphorylation of exogenous histone, as described in [S] .
Insulin secretion from PKC-depleted islets
Prolonged exposure to tumour-promoting phorbol esters causes a reduction or abolition of PKC activity, with consequent loss of various cellular functions, in a variety of cell types (see [lo] ). The loss of PKC activity from treated cells probably reflects an increase in the rate of degradation of the kinase within the cells [ 111. This appears to be a relatively specific means of down-regulating PKC, since cellular functions which are lost after such treatment can be restored by micro-injection of purified PKC into the treated cells 1121.
In our studies, isolated islets were cultured for 20-24 h in the presence of the PKC activator phorbol 12-myristate 13-acetate (PMA; 200 nM) to down-regulate PKC, or in the Abbreviations used: PKC, protein kinase C; DAG, diacylglycerol; PMA, phorbol 12-myristate 13-acetate; PDD, 4a-phorbol 12, 13-didecanoate; CCh, carbachol.
presence of the inactive phorbol ester 4a-phorbol 12,13-didecanoate (PDD; 200 nM) to serve as controls. In earlier experiments in which total PKC activity in broken cell preparations was measured, no detectable diolein-or PMAactivated PKC activity remained after 20-24 h treatment with PMA, although both diolein and PMA stimulated PKC activity in extracts from PDD-treated islets 171. In more recent experiments we have measured ion-exchange purified PKC activity in cytosolic and membrane fractions prepared from islets [8] . In control islets treated with PDD most of the PKC activity was found in the cytoplasmic fraction (472 k 59 fmol/min per islet, r n e a n f s .~.~. , n = 3 ) and much lower levels of activity were associated with a membrane fraction (44 k 6 fmol/min per islet). PMA treatment (2 1 h) virtually abolished cytoplasmic PKC activity (25 a 4 fmol/min per islet) without causing significant changes in the low levels of membrane-associated activity (40 f 9 fmol/min per islet).
As might be expected, given the abolition of PKC activity, insulin secretion from PMA-treated islets was not stimulated by a subsequent challenge with PMA, as shown in Fig. 1 . However, down-regulation of PKC by PMA treatment did not detectably inhibit glucose-induced insulin secretion from intact islets (Fig. l) , arguing against a major role for PMA/ diolein-stimulatable PKC as a regulator of glucose-induced insulin secretion. There is considerable evidence that glucose can stimulate the hydrolysis of membrane phosphoinositides to produce DAG, which may activate PKC, and inositol phosphates, which can release intracellular stores of Ca" (see [2] ). Whatever the importance of inositol phosphates in signal transduction in the B-cell, the results of our studies, and similar recent reports from other groups [ 51, suggest that the activation of PKC is not obligatory for the stimulation of insulin release by glucose, the major physiological insulin secretagogue.
Phospholipid hydrolysis in B-cells is stimulated by muscarinic cholinergic agonists, such as carbachol (CCh), which are known to enhance glucose-induced insulin secretion. Although there are differences between the phospholipid hydrolysis induced by CCh and that induced by glucose (see [2] ), there is evidence that cholinergic agonists may induce rapid increases in DAG concentrations [ 13, 141 . It is therefore feasible that cholinergic stimulation of insulin secretion is mediated by activation of PKC. Fig. 1 shows the effects of CCh on insulin secretion from PKC-depleted islets, and from control (PDD-treated) islets. CCh (500 p~) caused a marked enhancement of glucose-induced (20 mM) insulin secretion from PDD-treated islets. This response to CCh was significantly inhibited in PMA-treated (and thus PKC-depleted) islets, although the secretory response to 20 mM-glucose was comparable with control (PDD-treated) NUTRIENT REGULATION OF INSULIN SECRETION islets. The reduced secretory response to CCh in PKCdepleted islets cannot be accounted for by a reduction in CCh-induced phospholipase C activity because CCh had similar effects on phospholipase C activity in control (PDD- Vol. 18 115 treated) and PMA-treated islets, as assessed by the generation of radiolabelled inositol phosphates (Table l) . These results suggest that the activation of PKC may be responsible, at least in part, for the stimulation of insulin secretion by cholinergic agonists.
PKC translocation in islets
A role for PKC in cholinergic control of insulin secretion was supported by measurements of the redistribution of PKC activity within islet cells in response to insulin secretagogues. The activation of PKC is thought to involve translocation of the enzyme from the cytosol to membranes, where it associates with phosphatidylserine forming a catalytically active complex [ 1.51. Exposing islets to PMA (5 min, 37°C) produced a significant decrease in cytosolic PKC activity (control 275 f 19 fmol/min per islet; plus 500 nM-PMA, 140k 10 fmol/min per islet; 1'<0.01, n = 5 ) with a concomitant increase in membrane-associated activity (control undetectable; plus 500 nM-PMA, 4 3 k 7 fmol/min per islet, P <0.01), in accordance with other recent reports in insulin-secreting cell lines [ 16, 171. CCh had similar effects to PMA on the distribution of PKC activity in islets, as shown in Fig. 2 . Thus, incubation in the presence of CCh (5 min, 37°C) reduced cytosolic PKC activity and increased membrane-associated activity (Fig. 2) . It is worth noting that these experiments were performed in the presence of a sub-stimulatory concentration of glucose (2 mM), and that under these conditions cholinergic agonists d o not markedly stimulate insulin secretion [ 181. It would therefore appear that cholinergic agonists activate PKC in B-cells, but that this activation is not sufficient to initiate a secretory response per se. Furthermore, down-regulation of PKC activity by PMA-treatment inhibited, but did not totally abolish the secretory response to CCh (Fig. l) , also suggesting that activation of PKC is not the sole mechanism through which CCh modulates insulin release. In experiments similar to those using CCh, we have been unable to demonstrate significant effects of glucose (20 mM) on PKC translocation at times (2-10 min) when this concentration of glucose stimulated insulin secretion [8] and the production de novo of DA [14] . PKC is a family of isoenzymes which may have differing sensitivities to different activators [3] . It is conceivable that glucose activates only a minority subspecies of PKC whose translocation is not detectable in an assay which measures activity of all PKC isoenzymes, or that glucose activates an isoenzyme which does not translocate to membranes upon activation. An alternative explanation is that the DAG generated in response to glucose does not activate PKC, perhaps because of its cellular localization, and that the translocation of PKC is not obligatory for glucose-induced insulin secretion.
In conclusion, our studies using isolated islets of Langerhans in which PKC activity has been down-regulated by phorbol ester treatment suggest that PKC may not be an important mediator of glucose-induced insulin secretion, but suggest a role for PKC in the transduction of cholinergic stimulation of insulin secretion. These conclusions are supported by direct measurements of the translocation of PKC activity from cytosol to membranes in response to a cholinergic agonist.
In 1984 we emphasized [ l ] the criteria that had to be satisfied in order to implicate protein phosphorylation in regulation of insulin secretion or biosynthesis: (1) the presence in the pancreatic B-cell of the particular protein kinase must be established; ( 2 ) both endogenous substrate( s) and appropriate phosphatase(s) must be shown to be present; (3) changes in phosphorylation of a particular endogenous substratejs) should occur in parallel with changes in insulin secretion or biosynthesis in the intact cell; (4) the nature and role of the endogenous substrates should be established and the functional consequences of phosphorylation demonstrated. These criteria are still far from being satisfied for either biosynthesis or secretion of insulin. This may be attributed to our incomplete knowledge of the biomolecules involved in these processes. We review here some aspects of the current understanding of the relevance of protein phosphorylation to B-cell function.
Role of protein kinase A in the pancreatic B-cell
Protein kinase A has been detected and characterized in various B-cell preparations as reviewed in [l] . Type I and type I1 isoenzymes have been demonstrated in rat islets with properties similar to those found in other tissues [2] . Substrates for protein kinase A have been studied in intact islets Abbreviations used: TPA, 12-0-tetradecanoyl phorbol 13-acetate; MLCK, myosin light chain kinase; DHU, dehydrouramil.
of Langerhans prelabelled with ['zP]Pi and then stimulated with forskolin, an activator of adenylate cyclase; phosphopeptides were separated by SDS/gel electrophoresis [3] . Within 5 min forskolin evoked increased labelling of 25 and 30 kDa cytosolic and 23 and 32 kDa particulate phosphopeptides. In subcellular fractions incubated with purified catalytic subunit of protein kinase A, peptides phosphorylated included cytosolic species of 25 and 30 kDa and particulate species of 23 and 32 kDa. The 32 kDa phosphopeptide appeared to be a ribosomal protein and the 23 kDa peptide was localized to the secretory granule. Forskolin also elicited rapid dephosphorylation of two cytosolic peptides of molecular mass 18 and 32 kDa. In addition, a slow phosphorylation of a 15 kDa species identified as histone H 3 [4] was also observed in response to elevation of B-cell cyclic AMP. In electrically permeabilized islets, cyclic AMP was reported to cause rapid increases in phosphorylation of proteins of 25, 30, 57, 76 and 90 kDa, but the subcellular locations and nature of these substrates was not determined [ 5 1.
It is well established that an increase in B-cell cyclic AMP magnifies the secretory response to an initiator of secretion such as glucose (reviewed in [6] ). This potentiation of insulin secretion is accompanied by rapid phosphorylation of specific islet substrates for protein kinase A [3] , supporting a modulatory role for protein kinase A in the regulation of insulin secretion.
Early studies produced conflicting findings on a possible role of cyclic AMP in modulating insulin biosynthesis [7, 81; more recent studies, however, have provided evidence for a role for cyclic AMP in transcriptional regulation of the insulin gene. Northern-blot analysis demonstrated in both HIT
